Marker Therapeutics (NASDAQ:MRKR) Stock Rating Upgraded by Zacks Research

Marker Therapeutics (NASDAQ:MRKR) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Thursday, Zacks reports.

A number of other equities analysts also recently weighed in on the stock. Weiss Ratings downgraded shares of Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. HC Wainwright reissued a “buy” rating on shares of Marker Therapeutics in a research note on Friday, August 21st. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Marker Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $10.00.

Marker Therapeutics Stock Up 13.0%

MRKR stock traded up $0.12 during midday trading on Thursday, reaching $1.04. 1,145,148 shares of the company’s stock traded hands, compared to its average volume of 86,015. The company has a 50-day simple moving average of $1.17 and a two-hundred day simple moving average of $1.33. Marker Therapeutics has a 1-year low of $0.84 and a 1-year high of $2.46. The company has a market cap of $17.34 million, a price-to-earnings ratio of -2.54 and a beta of 1.53.

Marker Therapeutics (NASDAQ:MRKR) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.16. Equities research analysts forecast that Marker Therapeutics will post -0.64 EPS for the current year.

Institutional Trading of Marker Therapeutics

An institutional investor recently bought a new stake in Marker Therapeutics stock. Concurrent Investment Advisors LLC purchased a new position in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund purchased 67,963 shares of the company’s stock, valued at approximately $100,000. Concurrent Investment Advisors LLC owned 0.41% of Marker Therapeutics at the end of the most recent reporting period. 22.39% of the stock is owned by hedge funds and other institutional investors.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. The company’s approach uses tumor-specific T cells designed to recognize multiple tumor-associated antigens, with the goal of addressing the heterogeneity of solid tumors and potentially reducing the likelihood of treatment resistance.

Marker’s lead program is MT-601, an autologous multi-antigen-specific T-cell therapy being evaluated for pancreatic ductal adenocarcinoma.